Wall Street analysts expect Cambrex Co. (NYSE:CBM) to report sales of $156.35 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Cambrex’s earnings. The highest sales estimate is $158.13 million and the lowest is $154.76 million. Cambrex reported sales of $104.62 million in the same quarter last year, which indicates a positive year over year growth rate of 49.4%. The company is expected to issue its next earnings results on Thursday, November 14th.
On average, analysts expect that Cambrex will report full year sales of $648.72 million for the current year, with estimates ranging from $646.63 million to $652.19 million. For the next fiscal year, analysts expect that the firm will post sales of $659.73 million, with estimates ranging from $656.73 million to $662.96 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Cambrex.
CBM has been the topic of a number of recent research reports. William Blair cut shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price on the stock. in a research report on Wednesday, August 7th. ValuEngine lowered shares of Cambrex from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Craig Hallum lowered shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a research report on Monday, August 12th. Finally, Zacks Investment Research lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $52.00.
Several large investors have recently added to or reduced their stakes in CBM. BlackRock Inc. lifted its holdings in shares of Cambrex by 2.7% in the second quarter. BlackRock Inc. now owns 5,001,164 shares of the biotechnology company’s stock valued at $234,103,000 after purchasing an additional 132,617 shares in the last quarter. Vanguard Group Inc. lifted its position in Cambrex by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,504,246 shares of the biotechnology company’s stock valued at $164,034,000 after acquiring an additional 42,200 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Cambrex by 0.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,337,800 shares of the biotechnology company’s stock valued at $51,974,000 after buying an additional 3,589 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Cambrex by 16.8% during the 1st quarter. Lazard Asset Management LLC now owns 924,844 shares of the biotechnology company’s stock valued at $35,930,000 after buying an additional 133,133 shares during the period. Finally, American Capital Management Inc. lifted its holdings in shares of Cambrex by 14.3% during the 1st quarter. American Capital Management Inc. now owns 764,238 shares of the biotechnology company’s stock valued at $29,691,000 after buying an additional 95,441 shares during the period.
Cambrex stock traded up $0.12 during trading on Friday, reaching $59.70. The company had a trading volume of 6,817 shares, compared to its average volume of 465,796. Cambrex has a 12-month low of $33.80 and a 12-month high of $61.16. The stock’s 50 day moving average price is $59.63 and its two-hundred day moving average price is $47.98. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of 21.56, a PEG ratio of 4.65 and a beta of 2.19. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.77 and a current ratio of 2.44.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.